⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
IMTX News
Immatics N.V. Ordinary Shares
Insights Into the Booming Peptide Cancer Vaccines Market 2025-2031: Key Trends & Opportunities in Breast Cancer, Lung Cancer, Melanoma, Prostate Cancer, and Other Applications - ResearchAndMarkets.com
businesswire.com
IMTX
Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress
globenewswire.com
IMTX
Immatics Announces $125 Million Underwritten Offering
globenewswire.com
IMTX
Immatics Announces Third Quarter 2025 Financial Results and Business Update
globenewswire.com
IMTX
Immatics Achieves Clinical Proof-of-Concept of its Next-Generation TCR Bispecific (TCER®) Pipeline with Data on IMA402 (PRAME) and IMA401 (MAGEA4/8) and Announces Next Development Steps
globenewswire.com
IMTX